Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.52 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.52 |
| ▸ | TAAR1 | Q96RJ0 | 2/20 | 0.41 |
| ▸ | IMPDH2 | P12268 | 4/20 | 0.40 |
| ▸ | IMPDH1 | P20839 | 1/20 | 0.40 |
| ▸ | TYMP | P19971 | 2/20 | 0.39 |
| ▸ | HINT1 | P49773 | 2/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 4/20 | 0.38 |
| ▸ | ADORA2A | P29274 | 4/20 | 0.38 |
| ▸ | ADORA1 | P30542 | 4/20 | 0.38 |
| ▸ | ADORA2B | P29275 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | TSHR | P16473 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL441420 | 0.93 | TAS1R3 (0.44) | TAS1R3TAS1R1TAAR1IMPDH2IMPDH1 | |
| SCHEMBL2115347 | 0.91 | TAS1R3 (0.54) | TAS1R3TAS1R1TAAR1IMPDH2IMPDH1 | |
| SCHEMBL8669174 | 0.88 | TAAR1 (0.51) | TAAR1TYMPHINT1 | |
| SCHEMBL2115365 | 0.84 | PRMT5 (0.46) | ADORA3ADORA2AADORA2B | |
| SCHEMBL441421 | 0.83 | TYMP (0.48) | TAS1R3TAS1R1TAAR1IMPDH2IMPDH1 | |
| SCHEMBL2116135 | 0.82 | TYMP (0.38) | TAAR1IMPDH2IMPDH1TYMPHINT1 | |
| SCHEMBL2113123 | 0.82 | KDM4E (0.50) | TAS1R3TAS1R1TAAR1TYMPHINT1 | |
| SCHEMBL9155236 | 0.81 | TAS1R3 (0.36) | TAS1R3TAS1R1TAAR1 | |
| SCHEMBL9116771 | 0.81 | KDM4E (0.42) | TAS1R3TAS1R1TAAR1TYMPHINT1 | |
| SCHEMBL441118 | 0.80 | P2RY6 (0.39) | ADORA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8158770-B2 | Content dependent inhibitors of cytidine deaminases and uses thereof | UNIVERSITY OF ROCHESTER (US) | 2012-04-17 | — | — | US | disclosed |
| US-20090099105-A1 | Content dependent inhibitors of cytidine deaminases and uses thereof | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090099105-A1 | Content dependent inhibitors of cytidine deaminases and uses thereof | DCTD, CDA, ADA | TAS1R3 4055/4885TAS1R1 4039/4885TAAR1 4388/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.